Ionis Pharmaceuticals (IONS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -381,387 | -453,897 | -366,286 | -269,722 | -28,597 |
| Depreciation Amortization | 5,867 | -9,053 | -57 | 34,867 | 42,294 |
| Accounts receivable | 26,129 | 5,590 | -72,059 | 36,358 | 14,308 |
| Accounts payable and accrued liabilities | -15,360 | 15,990 | 8,119 | 1,094 | -6,000 |
| Other Working Capital | -51,215 | -209,390 | -77,260 | 7,571 | -113,818 |
| Other Operating Activity | 147,383 | 149,813 | 200,030 | -84,538 | 122,612 |
| Operating Cash Flow | $-268,583 | $-500,947 | $-307,513 | $-274,370 | $30,799 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -220,692 | -83,686 | -186,138 | -496,620 | 219,992 |
| PPE Investments | -51,444 | -45,280 | -23,805 | 238,362 | -11,955 |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -7,185 |
| Purchase Sale Intangibles | -5,640 | -5,061 | -4,184 | -4,378 | -5,946 |
| Other Investing Activity | -5,640 | -5,061 | -4,184 | -4,378 | -5,946 |
| Investing Cash Flow | $-277,776 | $-134,027 | $-214,127 | $-262,636 | $194,906 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 770,000 | N/A | 575,000 | N/A | 632,500 |
| Debt Repayment | -286,764 | -44,671 | -502,278 | -50,686 | -455,550 |
| Common Stock Issued | 192,604 | 522,729 | 49,442 | 6,373 | 101,317 |
| Other Financing Activity | 0 | 0 | 521,918 | -10,982 | -32,334 |
| Financing Cash Flow | $675,840 | $478,058 | $644,082 | $-55,295 | $245,933 |
| Exchange Rate Effect | 702 | -273 | 352 | -418 | -111 |
| Beginning Cash Position | 242,077 | 399,266 | 276,472 | 869,191 | 397,664 |
| End Cash Position | 372,260 | 242,077 | 399,266 | 276,472 | 869,191 |
| Net Cash Flow | $130,183 | $-157,189 | $122,794 | $-592,719 | $471,527 |
| Free Cash Flow | |||||
| Operating Cash Flow | -268,583 | -500,947 | -307,513 | -274,370 | 30,799 |
| Capital Expenditure | -51,444 | -45,280 | -23,805 | -15,721 | -11,955 |
| Free Cash Flow | -320,027 | -546,227 | -331,318 | -290,091 | 18,844 |